Abstract

Artificial liver support system (ALSS) therapy is widely used in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). We aimed to develop a predictive score to identify the subgroups who may benefit from plasma exchange (PE)-centered ALSS therapy. A total of 601 patients were retrospectively enrolled and randomly divided into a derivation cohort of 303 patients and a validation cohort of 298 patients for logistic regression analysis, respectively. Five baseline variables, including liver cirrhosis, total bilirubin, international normalized ratio of prothrombin time, infection and hepatic encephalopathy, were found independently associated with 3-month mortality. A predictive PALS model and the simplified PALS score were developed. The predicative value of PALS score (AUROC = 0.818) to 3-month prognosis was as capable as PALS model (AUROC = 0.839), R score (AUROC = 0.824) and Yue-Meng’ score (AUROC = 0.810) (all p > 0.05), and superior to CART model (AUROC = 0.760) and MELD score (AUROC = 0.765) (all p < 0.05). The PALS score had significant linear correlation with 3-month mortality (R2 = 0.970, p = 0.000). PALS score of 0–2 had both sensitivity and negative predictive value of > 90% for 3-month mortality, while PALS score of 6–9 had both specificity and positive predictive value of > 90%. Patients with PALS score of 3–5 who received 3–5 sessions of ALSS therapy had much lower 3-month mortality than those who received 1–2 sessions (32.8% vs. 59.2%, p < 0.05). The more severe patients with PALS score of 6–9 could still benefit from ≥ 6 sessions of ALSS therapy compared to ≤ 2 sessions (63.6% vs. 97.0%, p < 0.05). The PALS score could predict prognosis reliably and conveniently. It could identify the subgroups who could benefit from PE-centered ALSS therapy, and suggest the reasonable sessions.Trial registration: Chinese Clinical Trial Registry, ChiCTR2000032055. Registered 19th April 2020, http://www.chictr.org.cn/showproj.aspx?proj=52471.

Highlights

  • Artificial liver support system (ALSS) therapy is widely used in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-Acute-on-chronic liver failure (ACLF))

  • We found that five variables, namely liver cirrhosis (LC), total bilirubin (TBil), prothrombin time (PT)-international normalized ratio (INR), infection and hepatic encephalopathy (HE), were the independent predictors of 3-month prognosis in patients with HBV-ACLF treated with plasma exchange (PE)-centered ALSS therapy

  • The establishment of our PALS model is based on some classical parameters determining the Model for End-stage Liver Disease (MELD) s­ core[24], R ­score[22], Yue-Meng’ s­ core[25], classification and regression tree (CART) m­ odel[23], AARC s­ core[29], CLIF-C ACLF s­ core[5,30], and HBV-ACLF c­ riteria[4]

Read more

Summary

Introduction

Artificial liver support system (ALSS) therapy is widely used in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). We aimed to develop a predictive score to identify the subgroups who may benefit from plasma exchange (PE)-centered ALSS therapy. The PALS score could predict prognosis reliably and conveniently It could identify the subgroups who could benefit from PE-centered ALSS therapy, and suggest the reasonable sessions. Subgroups of patients with HBV-ACLF who could benefit from PE-centered ALSS therapy and factors affecting survival must be identified. Huang et al used classification and regression tree (CART) analysis and found that HBV-ACLF patients with a prothrombin time (PT) ≤ 27.8 s but hepatic encephalopathy (HE) may benefit from PE-centered ALSS therapy, especially when the total bilirubin level was ≤ 455 μmol/ L23. We compared the accuracy of our predictive model and score in predicting 3-month mortality with several earlier predictive models, including the CART ­model[23], MELD ­score[24], R ­score[22], and Yue-Meng’ s­ core[25]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call